ReviewACS omega2026
Ionic Liquids in Pharmaceuticals: A Scoping Review of Formulation Strategies.
Review in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- TransfersomILs: A Synergy to Boost the Skin Delivery of Hydroxycinnamic Acids.Pharmaceutics · 2026Article
- Design, Synthesis, and Biological Evaluation of Highly Functionalized Tetrahydro-β-carboline-imidazolium Hybrids Targeting Cholinesterases.Molecules (Basel, Switzerland) · 2026Article
- Ionic Liquid-Enabled Drug Delivery Systems: Benefits, Limitations, and Future Perspectives.Pharmaceutics · 2026Review
- Topical pyridostigmine for ocular myasthenia gravis: a translational hypothesis.Medical hypothesis, discovery & innovation ophthalmology journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ionic liquids (ILs) have rapidly emerged as multifunctional formulation tools capable of addressing long-standing challenges in drug delivery. This scoping review systematically assessed their pharmaceutical applications through a structured search of Scopus, PubMed, and Web of Science, yielding 1866 records, of which 91 experimental studies met the inclusion criteria. Across oral, injectable, topical, transdermal, nasal, and advanced delivery systems, ILs consistently improved the drug solubility, chemical stability, mucosal permeability, and overall biopharmaceutical performance. Choline- and imidazolium-based ILs were the most frequently investigated, demonstrating favorable safety profiles and significant pharmacokinetic benefitsincluding increases in maximum plasma concentration (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.